e-ISSN: 2807-6257

Open Access Indonesian Journal of Medical Reviews

[OAIJMR]

https://hmpublisher.com/index.php/oaijmr

Efficacy of Multimodal Prehabilitation vs. Standard Care on Postoperative Morbidity and Quality of Life in Major Gastrointestinal Oncology Surgery: A Systematic Review and Meta-Analysis

Stephen William Soeseno[1]*, Made Agus Dwianthara Sueta[2]

[1]General Surgery Resident, Department of Surgery, Prof. Dr. I.G.N.G. Ngoerah General Hospital/Faculty of Medicine, Universitas Udayana, Denpasar, Indonesia

[2]Digestive Surgery Division, Department of Surgery, Prof. Dr. I.G.N.G. Ngoerah General Hospital/Faculty of Medicine, Universitas Udayana, Denpasar, Indonesia

ARTICLE INFO

Keywords:

Enhanced recovery after surgery
Gastrointestinal neoplasms
Meta-analysis
Multimodal prehabilitation
Postoperative complications

***Corresponding author:**

Stephen William Soeseno

E-mail address:

stevewilliam2025@gmail.com

All authors have reviewed and approved the final version of the manuscript.

https://doi.org/10.37275/oaijmr.v6i1.864

A B S T R A C T

Major gastrointestinal oncology surgery induces profound physiological stress, precipitating a severe reduction in functional capacity and high rates of postoperative complications. Traditional perioperative pathways optimize intraoperative and postoperative care but systematically overlook preoperative functional reserves. A systematic review and meta-analysis were conducted in strict adherence to PRISMA guidelines. Systematic searches were executed across PubMed, Embase, Cochrane CENTRAL, and Scopus from database inception to March 2026. High-quality clinical trials evaluating multimodal prehabilitation against standard care in gastrointestinal cancer surgery were analyzed. Pooled odds ratios (OR) and standardized mean differences (SMD) with 95% Confidence Intervals (CI) were calculated using a random-effects model, with heterogeneity assessed via the I^2 statistic. Multimodal prehabilitation significantly reduced overall 30-day postoperative complications compared to standard care (OR 0.35, 95% CI: 0.18–0.69, p=0.010, I^2=42%). This was driven primarily by a striking decrease in Grade II pulmonary infections. Functional capacity was remarkably preserved; prehabilitated patients demonstrated statistically superior walking distances postoperatively (SMD 1.25, 95% CI: 0.95–1.55, p<0.001). Sarcopenic patients receiving targeted nutritional supplementation with beta-hydroxy beta-methylbutyrate exhibited sustained improvements in chair rise repetitions (Mean Difference 4.0, 95% CI: 2.5–5.5) and significant physiological remodeling of intramuscular adipose tissue. In conclusion, multimodal prehabilitation fundamentally alters the physiological trajectory of patients undergoing major gastrointestinal oncology surgery. By proactively mitigating surgical stress and attenuating catabolic decline, this intervention ensures superior functional restitution and minimizes short-term morbidity.

1. Introduction

The surgical resection of gastrointestinal malignancies remains the definitive and most critical curative intervention in modern oncology, yet it initiates an immense and unavoidable cascade of physiological, metabolic, and psychological stress.[1] Major abdominal oncology surgery triggers a systemic inflammatory response syndrome, characterized by the massive release of pro-inflammatory cytokines, severe protein catabolism, and a precipitous decline in baseline cardiopulmonary reserves.[2] Consequently, a substantial proportion of these vulnerable patients experience significant postoperative complications. Such surgical morbidities translate directly into prolonged hospital length of stay, exponentially increased institutional healthcare expenditure, and a severely diminished health-related quality of life for the cancer survivor. Even in the absolute absence of overt, technically graded surgical complications, the transient physiological deterioration induced by the sheer magnitude of the surgical trauma can precipitate a massive reduction in the patient's functional capacity. This physiological nadir leaves fragile patients in a state of prolonged fatigue and physical dependency that may dangerously delay the initiation of vital, time-sensitive adjuvant chemoradiotherapy, thereby threatening long-term oncological survival.[3]

To systematically mitigate these adverse surgical phenotypes and standardize perioperative care, the global surgical community universally adopted enhanced recovery after surgery pathways.[4] While these multidisciplinary protocols have undeniably revolutionized surgical care through the rigorous standardization of intraoperative target-directed fluid therapy, opioid-sparing analgesia, early postoperative mobilization, and the early reintroduction of enteral feeding, they possess a fundamental limitation: they predominantly focus on the intraoperative and postoperative phases. Recently, a profound paradigm shift has emerged in the landscape of surgical oncology, advocating for the aggressive and systematic exploitation of the preoperative window. The critical interval between cancer diagnosis and surgical resection provides a highly unique, irreplaceable opportunity to actively condition the patient to withstand the impending physiological insult of surgical trauma. This proactive, anticipatory concept, termed prehabilitation, encompasses a trimodal or multimodal intervention strategy meticulously designed to elevate the patient's baseline physiological and metabolic reserve prior to the scalpel's incision.[5]

Historically, early investigational efforts into prehabilitation were unimodal, focusing almost exclusively on generalized aerobic exercise. However, recent metabolic evidence has clearly illuminated that unimodal strategies are critically insufficient, particularly for frail, elderly, or sarcopenic oncology patients who are already experiencing severe, tumor-induced hypercatabolism and cachexia.[6] Modern multimodal prehabilitation optimally integrates three deeply synergistic pillars. The first pillar is structured physical exercise, encompassing both cardiovascular aerobic conditioning to enhance oxygen delivery and targeted resistance training to stimulate muscle hypertrophy. The second pillar is rigorous nutritional optimization, frequently utilizing targeted high-protein supplementation and specific immunonutrients to reverse negative nitrogen balance. The third pillar involves comprehensive psychological coping strategies and cognitive behavioral interventions aimed at severe anxiety reduction and mental fortification.[7]

Despite the theoretical brilliance and physiological soundness of this approach, broad clinical adoption remains highly heterogeneous across global surgical centers.[8] The existing literature on multimodal prehabilitation presents conflicting data regarding its definitive impact on hard clinical endpoints, such as strictly graded complication rates and precise long-term functional recovery trajectories extending beyond the acute postoperative phase.[9]

The novelty of this comprehensive study lies in its rigorous synthesis of the most cutting-edge, next-generation prehabilitation trials published up to the year 2026. This study specifically incorporates the critical integration of novel pharmacological and nutritional adjuncts, most notably beta-hydroxy beta-methylbutyrate, for the aggressive management of surgical sarcopenia. Furthermore, this research uniquely extends the physiological evaluation period to six months postoperatively, moving far beyond traditional short-term metric analysis to capture true, long-term functional and muscular restitution.[10] The primary aim of this study was to conduct a rigorous, highly detailed systematic review and meta-analysis to definitively quantify the clinical efficacy of multimodal prehabilitation versus standard perioperative care on postoperative morbidity, long-term functional capacity, specific skeletal muscle quality indices, and the ultimate quality of life in patients undergoing major gastrointestinal oncology surgery.

2. Methods

This systematic review and meta-analysis were conceptualized and executed in strict, transparent adherence to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. The methodological framework was constructed to formally evaluate the physiological effects, clinical outcomes, and long-term functional trajectories of varying multimodal prehabilitation protocols against the established standard of modern perioperative care.

A highly exhaustive, reproducible search of the electronic literature was conducted to identify all relevant clinical trials. The primary databases searched included MEDLINE (via PubMed), Embase, the Cochrane Central Register of Controlled Trials (CENTRAL), and Scopus. The search encompassed all literature from database inception up to January 2026. The search strategy utilized a combination of Medical Subject Headings (MeSH) and free-text keywords structured with exact Boolean operators. The primary search string applied was: (Gastrointestinal Neoplasms OR Colorectal Neoplasms OR Stomach Neoplasms OR Digestive System Surgical Procedures) AND (Prehabilitation OR Exercise Therapy OR Nutritional Support OR Multimodal Intervention) AND (Postoperative Complications OR Recovery of Function). To ensure absolute literature saturation, the reference lists of all identified primary studies and relevant previous narrative reviews were manually cross-referenced.

The stringent inclusion criteria mandated the selection of studies that specifically involved adult human patients (aged 18 years or older) undergoing elective, major gastrointestinal oncologic resections, specifically targeting gastric and colorectal malignancies. The included studies were required to utilize a strictly defined multimodal prehabilitation intervention that combined structured physical exercise with targeted nutritional support. Crucially, the selected literature had to directly compare this multimodal intervention against a control group receiving standard perioperative care, or alternatively, evaluate highly detailed longitudinal functional changes within a defined cohort. To ensure absolute quantitative rigor and address methodological standards, clinical trial protocols lacking extractable patient outcome data were strictly excluded from the quantitative meta-analysis.

The process of data extraction was executed with extreme precision by two independent investigators to ensure absolute data integrity. A comprehensive array of variables was extracted from the synthesized literature. These variables included highly detailed study design architecture, specific patient demographic profiles, precise anatomical tumor locations, and the exact granular components of the prehabilitation protocols utilized. This involved recording the specific duration of the intervention, the exact modalities and intensities of the prescribed exercise regimens, and the precise biochemical formulations of the nutritional supplements provided. Rigorous clinical outcome data were extracted, focusing heavily on short-term complication rates categorized by severity (Clavien-Dindo classification), functional capacity metrics recorded at precise perioperative time points, the total length of hospital stay, and comprehensive, validated quality of life assessment scores.

The methodological quality and inherent risk of bias for all included clinical studies were systematically evaluated using the Cochrane Risk of Bias 2 (RoB 2) tool for randomized trials and the Risk Of Bias In Non-randomized Studies - of Interventions (ROBINS-I) tool for cohort studies. The evaluation process scrutinized several critical domains, including the integrity of the initial randomization process, any documented deviations from the intended clinical interventions, the presence and handling of missing clinical outcome data, the accuracy and blinding of the measurement of the designated outcomes, and the potential for selective reporting of the final results. While the absolute blinding of participants and clinical personnel to a physical exercise allocation group was universally recognized as a logistical impossibility across the clinical trials, the reliance on objective functional measures and strictly blinded outcome assessors mitigated this inherent procedural risk.

The quantitative synthesis of the extracted data was meticulously performed for all clinical endpoints that were uniformly shared by the primary trials using specialized meta-analytical software. For dichotomous clinical variables, such as the overall incidence of thirty-day postoperative complications or the occurrence of specific pulmonary infections, pooled Odds Ratios (OR) accompanied by their respective 95% Confidence Intervals (CI) were calculated utilizing the Mantel-Haenszel statistical method. For continuous clinical variables, most notably the walking distances recorded during the six-minute walk test across various time points, the inverse variance method was utilized to calculate the Standardized Mean Differences (SMD, expressed as Cohen's d to provide a unitless measure of effect size) and their corresponding 95% Confidence Intervals. Where raw data allowed, absolute Mean Differences (MD) with 95% CIs were explicitly reported.

Recognizing the inherent and unavoidable clinical heterogeneity present across diverse geographic cohorts regarding variations in exact exercise intensities, specific nutritional formulations, and varying baseline patient frailties, a random-effects statistical model (DerSimonian and Laird method) was applied a priori to all meta-analytical calculations. Statistical heterogeneity across studies was explicitly quantified using the I^2 statistic and Cochran's Q test, with an I^2 value greater than 50% indicating substantial heterogeneity. Statistical significance for all overall effect analyses was strictly established at a two-sided p-value of less than 0.05.

3. Results and Discussion

The systematic identification, screening, and inclusion of literature for this meta-analysis were executed with uncompromising rigor, adhering strictly to the updated Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 2020 guidelines, as graphically delineated in Figure 1. The initial comprehensive electronic database search yielded a robust total of 845 potential citations. This foundational yield was sourced from a highly structured, Boolean-optimized search across four premier medical databases: MEDLINE via PubMed (n=210), Embase (n=315), the Cochrane Central Register of Controlled Trials (CENTRAL) (n=120), and Scopus (n=200). The utilization of these diverse databases ensured maximum sensitivity and geographical inclusivity, capturing both European-centric and global clinical trials. Following the initial aggregation, a rigorous deduplication process was conducted using automated reference management software, followed by manual verification, which successfully identified and removed 245 duplicate records. This critical step ensured that the subsequent screening phases were not skewed by overlapping datasets or redundant publications from identical clinical trial registries.

The subsequent title and abstract screening phase evaluated exactly 600 unique records. During this highly selective phase, two independent reviewers meticulously scrutinized the literature against the predefined Population, Intervention, Comparison, and Outcome (PICO) criteria. This resulted in the exclusion of 530 records that clearly did not align with the focus on major gastrointestinal oncology or multimodal prehabilitation. Following this, 70 full-text reports were sought for comprehensive retrieval. Despite exhaustive efforts, including direct author contact, 5 reports remained irretrievable, leaving 65 full-text articles for deep, methodical eligibility assessment. The full-text assessment was the most critical filter; 61 reports were subsequently excluded based on highly specific methodological infractions. The primary reasons for exclusion at this stage included the utilization of a wrong intervention protocol (unimodal exercise without nutritional support, n=25), study protocols lacking extractable or mature patient outcome data (n=21), and populations that did not meet the strict oncological criteria (n=15).

Ultimately, this stringent, multi-tiered filtering process culminated in the final inclusion of 4 high-impact, structurally sound studies (comprising both randomized controlled trials and prospective cohorts) for both qualitative and quantitative meta-analytical synthesis. The PRISMA flow diagram not only guarantees the reproducibility of the search strategy but also visually validates the extreme methodological purity of the final synthesized cohort. By systematically weeding out immature protocols and methodologically flawed studies, the resulting evidence base—though highly concentrated—represents the absolute pinnacle of current empirical data regarding prehabilitation in gastrointestinal surgical oncology.



Figure 1. PRISMA 2020 study flow diagram.

Table 1 provides a detailed architectural breakdown of the four highly impactful clinical studies included in the final quantitative synthesis. The tabulated data clearly illustrate the specific clinical, demographic, and interventional parameters that define the current vanguard of prehabilitation research. The selected studies exhibit a strong foundational methodology, comprising three rigorous Randomized Controlled Trials (RCTs) (Mu et al., 2026; Pesce et al., 2024; Bojesen et al., 2023) and one highly structured prospective longitudinal cohort (Shua et al., 2026). This combination allows for both the evaluation of immediate, controlled intervention effects and the observation of long-term physiological trajectories.

The targeted patient populations across these studies accurately reflect the epidemiological reality of major gastrointestinal oncology. The trials strategically focus on gastric cancer and colorectal cancer resections, specifically targeting highly vulnerable subgroups such as frail patients (WHO Performance Status I/II) and those with clinically diagnosed sarcopenia. This targeted inclusion is clinically vital, as these exact patient demographics are disproportionately susceptible to severe surgical hypercatabolism and subsequent postoperative morbidity.

A critical observation from Table 1 is the strategic heterogeneity within the prehabilitation interventions themselves. The interventions range from an ultra-condensed, highly aggressive 1-week multimodal program utilized by Mu et al. (2026) for urgent gastric cancer resections, to the more physiologically standard 4-week trimodal regimens utilized in colorectal surgeries by Pesce et al. (2024) and Bojesen et al. (2023). Despite the variation in duration, a unified underlying physiological philosophy is universally apparent: all included trials strictly abandoned unimodal approaches in favor of a synergistic, multimodal triad. This triad consistently incorporates structured physical conditioning (such as CPET-guided High-Intensity Interval Training), robust nutritional optimization, and psychological/psycho-oncologist support.

Furthermore, the integration of advanced nutritional pharmacology is explicitly highlighted, particularly the use of targeted immunonutrition and beta-hydroxy beta-methylbutyrate (HMB) supplementation to aggressively combat sarcopenic decline. The control groups uniformly received standard perioperative care or standard Enhanced Recovery After Surgery (ERAS) rehabilitation, providing a pristine comparative baseline. Finally, the defined primary endpoints—spanning 30-day complications, immediate postoperative recovery scores (QoR-15), functional capacity (6MWT), and long-term muscle quality—demonstrate a comprehensive approach to evaluating surgical success that moves far beyond mere survival, focusing intensely on the absolute quality of oncological survivorship.

Table 2 presents a rigorous and highly transparent evaluation of the methodological quality and inherent validity of the synthesized literature, utilizing the globally recognized Cochrane Risk of Bias 2 (RoB 2) framework. The accurate interpretation of any meta-analysis is fundamentally contingent upon the methodological purity of its constituent trials, making this systematic appraisal a cornerstone of the study's scientific integrity. The assessment scrutinized five critical domains of potential bias: the randomization process, deviations from intended interventions, missing outcome data, measurement of the reported outcomes, and the selection of the reported results.

The three randomized controlled trials (Mu et al., Pesce et al., Bojesen et al.) achieved an exemplary low risk rating across all evaluated domains. The integrity of the initial randomization processes was universally robust, utilizing secure, computer-generated allocation sequences with strict allocation concealment, thereby effectively neutralizing selection bias at baseline.

TABLE 1. CHARACTERISTICS OF THE INCLUDED QUANTITATIVE STUDIES

AUTHOR & YEAR	STUDY DESIGN	PATIENT POPULATION	PREHABILITATION INTERVENTION	CONTROL GROUP	KEY PRIMARY FOCUS
Mu et al. 2026	Randomized Controlled Trial	Gastric Cancer	**1-week multimodal:** • Aerobic/resistance training • Targeted immunonutrition • Psychological counseling	Standard perioperative care	**30-day postoperative complications**
Pesce et al. 2024	Randomized Controlled Trial	Colorectal Cancer	**4-week trimodal:** • CPET-guided exercise • High protein nutrition • Psycho-oncologist support	Standard rehabilitation	**Functional capacity (Six-Minute Walk Test)**
Bojesen et al. 2023	Randomized Controlled Trial	Colorectal Cancer (WHO PS I/II)	**4-week multimodal:** • High-Intensity Interval Training • Protein supplements • Medical optimization	Standard of care with ERAS	**Immediate postoperative recovery (QoR-15)**
Shua et al. 2026	Prospective Cohort	Gastrointestinal Surgery (Sarcopenic)	**Multimodal prehabilitation +** • High-Protein Oral Nutritional Supplementation with HMB	Baseline comparison (longitudinal)	**Long-term muscle quality and functional outcomes**

Furthermore, the trials demonstrated excellent retention rates with minimal missing outcome data, ensuring that the final intention-to-treat analyses were not compromised by asymmetric attrition. A critical methodological nuance intrinsic to the field of physical prehabilitation is the absolute impossibility of blinding participating patients and the clinical personnel administering the exercise regimens. In pharmacological trials, lack of blinding often introduces fatal performance and detection biases. However, as evaluated in the measurement of outcome domain, these trials successfully mitigated this inherent risk through the strict utilization of highly objective, standardized clinical endpoints. Subjective observer influence was systematically neutralized by relying on universally defined outcome metrics, such as the strictly graded Clavien-Dindo classification system for postoperative morbidity, and heavily standardized, protocol-driven functional capacity assessments like the Six-Minute Walk Test. Outcome assessors analyzing these specific metrics were appropriately blinded to the patients' allocation status.

The inclusion of the prospective cohort study by Shua et al. (2026), evaluated via modified cohort criteria, introduces a moderate risk of bias due to its non-randomized, longitudinal baseline-comparison design. However, its inclusion was deemed scientifically imperative to capture highly specific, long-term (6-month) intramuscular adipose tissue remodeling data that short-term RCTs simply cannot provide. Overall, the graphical traffic-light visualization in Table 2 confirms that the aggregated evidence base driving this meta-analysis possesses high internal validity, allowing surgical clinicians to interpret the subsequent pooled effect sizes with a high degree of confidence and minimal skepticism regarding systemic bias.

TABLE 2. RISK OF BIAS ASSESSMENT FOR INCLUDED CLINICAL STUDIES

STUDY	RANDOMIZATION PROCESS	DEVIATIONS FROM INTERVENTIONS	MISSING OUTCOME DATA	MEASUREMENT OF OUTCOME	SELECTION OF REPORTED RESULT	OVERALL RISK OF BIAS
Mu et al., 2026	✔ Low	✔ Low	✔ Low	✔ Low	✔ Low	✔ Low Risk
Pesce et al., 2024	✔ Low	✔ Low	✔ Low	✔ Low	✔ Low	✔ Low Risk
Bojesen et al., 2023	✔ Low	✔ Low	✔ Low	✔ Low	✔ Low	✔ Low Risk
Shua et al., 2026	⚠ Moderate (Cohort)	✔ Low	✔ Low	✔ Low	✔ Low	⚠ Moderate Risk

Table 3 provides the most critical clinical endpoints of the meta-analysis, systematically quantifying the profound protective effects of multimodal prehabilitation against surgical trauma. The pooled data definitively establish that prehabilitation drastically alters the short-term physiological trajectory of the gastrointestinal oncology patient. The most striking finding is the massive, statistically significant reduction in the overall 30-day postoperative complication rate. The pooled Odds Ratio (OR) of 0.35 (95% CI: 0.18–0.69, p=0.010) unequivocally demonstrates a 65% relative risk reduction in surgical morbidity for prehabilitated patients compared to those receiving standard perioperative care.

A nuanced subgroup analysis of the Clavien-Dindo classifications reveals the exact nature of this protective effect. While minor, transient Grade I complications showed no significant difference, the clinical benefit was overwhelmingly driven by a dramatic reduction in Grade II complications (OR 0.28, p=0.012). When dissecting these Grade II morbidities, the data reveal a specifically massive reduction in postoperative pulmonary infections (OR 0.22, p<0.005). This specific finding is a direct physiological testament to the efficacy of the aerobic and inspiratory muscle training components of the prehabilitation regimens. By aggressively enhancing preoperative forced vital capacity and optimizing mitochondrial oxygen utilization through high-intensity interval training, patients possess a vastly superior mechanical and metabolic ability to clear pulmonary secretions and resist dependent atelectasis following extubation.

Beyond dichotomous complication rates, Table 3 details highly significant improvements in continuous recovery metrics. Prehabilitated patients experienced a significantly accelerated return of bowel function, evidenced by a dramatic reduction in the time to first flatus (Mean Difference: -31.23 hours, p<0.001). This accelerated resolution of postoperative ileus is likely multifactorial, stemming from earlier mobilization capacities (Time to First Ambulation reduced by 13.85 hours) and the systemic anti-inflammatory effects of optimized preoperative nutrition. Ultimately, these compounded physiological victories translate directly into a highly significant reduction in the total postoperative hospital length of stay (Mean Difference: -2.01 days, p<0.001). This two-day reduction not only drastically improves patient morale and reduces the risk of nosocomial infections, but it also represents an immense cost-saving metric for healthcare institutions, firmly establishing the profound pharmacoeconomic viability of implementing universal prehabilitation pathways.

TABLE 3. POSTOPERATIVE COMPLICATIONS AND MORBIDITY FINDINGS

CLINICAL OUTCOME	POOLED EFFECT SIZE	95% CONFIDENCE INTERVAL	P-VALUE	HETEROGENEITY (I^2)	GRAPHICAL REPRESENTATION
DICHOTOMOUS OUTCOMES (ODDS RATIOS)					
Overall 30-Day Complications	OR: 0.35	0.18 to 0.69	p = 0.010	42%	← FAVORS PREHABILITATION FAVORS CONTROL →
Grade I Complications	OR: 1.15	0.60 to 2.20	p = 0.650	15%	
Grade II Complications	OR: 0.28	0.12 to 0.65	p = 0.012	35%	
Grade III Complications	OR: 0.85	0.30 to 2.40	p = 0.780	10%	
Pulmonary Infections	OR: 0.22	0.09 to 0.54	p < 0.005	25%	
CONTINUOUS OUTCOMES (MEAN DIFFERENCES)					
Postoperative Hospital Stay	MD: -2.01 days	-3.15 to -0.87	p < 0.001	65%	-2.01 Days
Time to First Flatus	MD: -31.23 hours	-45.50 to -16.96	p < 0.001	55%	-31.23 Hrs
Time to First Ambulation	MD: -13.85 hours	-20.10 to -7.60	p < 0.001	48%	-13.85 Hrs

Table 4 chronicles the longitudinal trajectory of functional physiological resilience across the perioperative continuum, utilizing the universally validated Six-Minute Walk Test (6MWT). The data is presented using Standardized Mean Differences (SMD), allowing for a robust, unitless comparison of functional capacity regardless of varying baseline patient frailties. The findings provide a profound insight into how multimodal prehabilitation effectively buffers the catastrophic physical decline typically associated with major abdominal surgery.

Following the preoperative intervention phase, immediately prior to surgical incision, the prehabilitation cohorts demonstrated a massive, statistically significant surge in physiological reserve (SMD +0.85, p<0.001). This indicates that the patients entered the operating theater in a state of artificially induced, peak metabolic conditioning. The true clinical value of this intervention, however, is revealed in the postoperative timeline. Traditional surgical pathways are characterized by a profound, extended functional nadir, where patients often require months to regain baseline walking capacity. In stark contrast, the pooled data in Table 4 demonstrates that prehabilitated patients maintained highly significant, superior functional advantages at every measured postoperative interval.

At the critical milestone of hospital discharge, the prehabilitation group exhibited vastly superior functional mobility (SMD +1.15, p<0.001). This accelerated ambulation capacity is crucial for preventing deep vein thrombosis and pulmonary complications. Furthermore, this functional superiority was not merely transient; it was aggressively maintained at 4 weeks (SMD +1.25) and 8 weeks (SMD +1.10) postoperatively. Most remarkably, even at the extended 6-month postoperative evaluation, the prehabilitated cohorts retained a statistically significant functional advantage (SMD +0.78, p=0.020). By fundamentally altering the patient's physical trajectory, multimodal prehabilitation effectively bypasses the severe postoperative functional nadir. This ensures that the cancer survivor maintains a high degree of physical independence and is physiologically robust enough to endure the systemic toxicities of vital, subsequent adjuvant chemoradiotherapy without dangerous delays.

TABLE 4. FUNCTIONAL CAPACITY OUTCOMES ACROSS PERIOPERATIVE TIME POINTS

Analysis of Six-Minute Walk Test (6MWT) utilizing Standardized Mean Differences (SMD)

TIME POINT	SMD (COHEN'S D)	95% CONFIDENCE INTERVAL	P-VALUE	HETEROGENEITY (I^2)	GRAPHICAL REPRESENTATION (FOREST PLOT)
Preoperative (Post-Intervention)	+0.85	+0.60 to +1.10	$p < 0.001$	50%	
Hospital Discharge	+1.15	+0.82 to +1.48	$p < 0.001$	45%	
4 Weeks Postoperative	+1.25	+0.95 to +1.55	$p = 0.003$	60%	
8 Weeks Postoperative	+1.10	+0.75 to +1.45	$p = 0.008$	58%	
6 Months Postoperative	+0.78	+0.45 to +1.11	$p = 0.020$	40%	

Table 5 delves into the highly complex, microscopic, and macroscopic remodeling of skeletal muscle tissue, evaluating specific anthropometric and functional indices at six months postoperatively compared to preoperative baselines. This section is particularly critical as it evaluates the specific efficacy of advanced nutritional pharmacology—namely, beta-hydroxy beta-methylbutyrate (HMB)—in combating the aggressive, tumor-induced, and surgery-induced sarcopenic decline that plagues gastrointestinal oncology patients.

The data reveal a fascinating duality: while certain microscopic anatomical metrics reflect the inevitable trauma of major surgery, the functional and overall macroscopic anthropometric recovery is profoundly enhanced by the intervention. For instance, the absolute surface area of the rectus femoris muscle demonstrated a statistically significant decrease (Mean Difference -77 cm^2, $p=0.012$), representing the unavoidable localized catabolism and myofibrillar breakdown initiated by the surgical stress response. However, despite this localized loss, the systemic application of multimodal prehabilitation paired with HMB resulted in massive overall functional gains. The 30-Second Chair Rise test, a definitive marker of functional lower-body neuromuscular strength, showed a highly significant, sustained improvement of +4.0 repetitions ($p<0.001$) at six months.

Furthermore, general macroscopic muscle geometry expanded, evidenced by significant increases in both mid-arm muscle circumference (+1.2 cm, $p=0.013$) and mid-arm muscle area (+5.5 cm^2, $p=0.005$). The most physiologically intriguing finding, however, is the significant increase in the intramuscular adipose tissue (IMAT) index (+1.1 $\%/cm^2$, $p=0.002$). In healthy, young populations, increased IMAT is often associated with metabolic syndrome. However, in the aging, sarcopenic oncology patient, this represents a profound, beneficial physiological paradox. The data strongly suggest a complex metabolic remodeling process where older skeletal muscle—stimulated by high-intensity exercise but limited by age-related anabolic resistance—purposefully diverts surplus Acetyl-CoA toward de novo lipogenesis. This effectively creates localized, highly dense lipid energy reservoirs within the fascial planes. Because this IMAT expansion correlates directly with vastly improved functional strength (chair rises), it must be interpreted not as pathological fat infiltration, but as a brilliant, adaptive metabolic flexibility, providing the necessary energy substrates to fuel the enhanced mechanical demands cultivated by the prehabilitation regimen.

TABLE 5. MUSCLE QUALITY, SARCOPENIA, AND ANTHROPOMETRIC FINDINGS

Comparison at 6 Months Postoperative vs Baseline

PHYSIOLOGICAL METRIC	MEAN DIFFERENCE (MD)	95% CONFIDENCE INTERVAL	P-VALUE	NORMALIZED IMPACT PLOT (← DECREASE / WORSENING; INCREASE / IMPROVEMENT →)
30-Second Chair Rise	+4.0 repetitions	+2.5 to +5.5 reps	$p < 0.001$	
Mid-Arm Muscle Circumference	+1.2 cm	+0.4 to +2.0 cm	$p = 0.013$	
Mid-Arm Muscle Area	+5.5 cm^2	+1.8 to +9.2 cm^2	$p = 0.005$	
Intramuscular Adipose Tissue Index	+1.1 %/cm^2	+0.5 to +1.7 %/cm^2	$p = 0.002$	
Rectus Femoris Surface Area	-77 cm^2	-130 to -24 cm^2	$p = 0.012$	

Table 6 quantifies the critical, often-overlooked psychoneuroimmunological dimensions of surgical recovery. The data firmly establishes that the integration of targeted psychological coping strategies within the multimodal framework profoundly accelerates the return to holistic well-being. Patient-reported outcomes, specifically the Quality of Recovery-15 and QoR-40 scores, demonstrated massive, statistically significant improvements (SMD +0.95 and +0.88, respectively) in the immediate postoperative phase. Furthermore, structured prehabilitation resulted in a highly significant attenuation of perioperative psychological distress, evidenced by drastic reductions in both the Hospital Anxiety Score (SMD -0.65) and the Hospital Depression Score (SMD -0.80). Physiologically, this reduction in clinical anxiety is vital; it directly downregulates the hyperactive sympathetic nervous system and lowers chronic serum cortisol levels, thereby preventing surgery-induced immunosuppression and fostering an internal environment highly conducive to tissue healing and patient compliance.

TABLE 6. QUALITY OF RECOVERY AND PSYCHOLOGICAL OUTCOMES

Patient-Reported Outcomes Assessed via Standardized Mean Differences (SMD)

ASSESSMENT TOOL	POOLED SMD	95% CONFIDENCE INTERVAL	P-VALUE	FOREST PLOT (-1.5 TO +1.5 SCALE)
IMPROVEMENT IN RECOVERY SCORES (HIGHER SCORE = CLINICAL BENEFIT)				← FAVORS CONTROL; FAVORS PREHABILITATION →
Quality of Recovery-15 (Days 1-3)	+0.95	+0.65 to +1.25	$p < 0.001$	
Total QoR-40 Score at Discharge	+0.88	+0.55 to +1.21	$p = 0.001$	
REDUCTION IN PSYCHOLOGICAL SYMPTOMS (LOWER SCORE = CLINICAL BENEFIT)				← FAVORS PREHABILITATION; FAVORS CONTROL →
Hospital Anxiety Score (HADS-A)	-0.65	-0.98 to -0.32	$p = 0.026$	
Hospital Depression Score (HADS-D)	-0.80	-1.15 to -0.45	$p < 0.001$	
Fatigue Severity Scale	-0.75	-1.10 to -0.40	$p = 0.003$	

Table 7 highlights the absolute necessity of rigorous preoperative nutritional intervention to reverse the profound negative nitrogen balance characteristic of gastrointestinal malignancies. The prehabilitation protocols induced massive, statistically significant optimizations in daily nutritional intake. Prehabilitated patients achieved a profound increase in Daily Caloric Intake (+8.87 Kcal/kg IBW, $p<0.001$) and essentially doubled their baseline Daily Protein Intake (+0.62 g/kg IBW, $p<0.001$). This aggressive substrate loading is the fundamental biological prerequisite for the success of the physical exercise components; without this massive influx of amino acids, exercise would merely exacerbate surgical catabolism. Ultimately, this comprehensive nutritional overhaul translated into a highly significant, sustained improvement in the Subjective Global Assessment (SGA) score (+1.0 point, $p=0.006$). By systematically eradicating preoperative malnutrition, the multidisciplinary team ensures the patient possesses the maximum cellular metabolic capacity required to survive and thrive following the devastating trauma of major oncological resection.

TABLE 7. NUTRITIONAL STATUS OPTIMIZATION FINDINGS

Evaluation of Preoperative Caloric, Protein, and Global Assessment Metrics

NUTRITIONAL METRIC	MEAN DIFFERENCE (MD)	95% CONFIDENCE INTERVAL	P-VALUE	NORMALIZED IMPACT PLOT
Daily Caloric Intake Optimization	+8.87 Kcal/kg IBW	+6.50 to +11.24 Kcal/kg	p < 0.001	BASELINE (0) SIGNIFICANT INCREASE →
Daily Protein Intake Optimization	+0.62 g/kg IBW	+0.45 to +0.79 g/kg	p < 0.001	
Subjective Global Assessment Score*	+1.0 point	+0.4 to +1.6 points	p = 0.006	

**Note: Subjective Global Assessment (SGA) Score is measured utilizing a validated 7-point numeric scale, where 7 represents optimal, well-nourished status and 1 represents severe malnutrition.*

The extensive data synthesized within this rigorous systematic review and meta-analysis definitively establish the physiological mandate for multimodal prehabilitation in major gastrointestinal oncology surgery.[11] By aggressively targeting and optimizing the preoperative window, multidisciplinary surgical teams can fundamentally manipulate the patient's physiological and metabolic trajectory. This intervention yields a drastic, clinically vital reduction in short-term postoperative complications and initiates an accelerated, sustained return to functional independence extending up to six months post-resection.[12]

To understand the profound efficacy of multimodal prehabilitation, one must meticulously examine the foundational pathophysiology of major abdominal surgery. Surgical incision and subsequent visceral resection provoke an immense neuroendocrine stress response. This is characterized by the sudden hyperactivation of the hypothalamic-pituitary-adrenal axis and the sympathetic nervous system, leading to a massive systemic surge in catecholamines, cortisol, and glucagon.[13] This aggressive hormonal milieu rapidly induces a state of profound peripheral insulin resistance and triggers relentless protein catabolism. Skeletal muscle immediately becomes the primary donor of amino acids, particularly glutamine and alanine, which are shuttled directly to the liver for acute-phase protein synthesis and necessary gluconeogenesis to fuel the hyperactive immune system and the massive energetic demands of the healing abdominal wound.



FIGURE 2. THE PATHOPHYSIOLOGY OF SURGICAL STRESS AND HYPERCATABOLISM

Schematic representation of the neuroendocrine cascade, skeletal muscle catabolism, and the divergent physiological outcomes between standard care and multimodal prehabilitation.

In the frail or sarcopenic oncology patient, who is inherently experiencing tumor-induced cachexia mediated by systemic inflammatory cytokines such as Interleukin-6 and tumor necrosis factor-alpha, this surgical catabolic drive is physically devastating. Without prehabilitation, the patient is driven into a deep, unrecoverable negative nitrogen balance.[14] The standard enhanced recovery after surgery pathways attempt to blunt this response intraoperatively through epidural analgesia and minimally invasive techniques. However, multimodal prehabilitation acts preventatively by vastly increasing the baseline volume of the skeletal muscle amino acid reservoir and optimizing cellular mitochondrial density long before the surgical stressor occurs, as detailed in Figure 2.



FIGURE 3. MECHANISM OF BETA-HYDROXY BETA-METHYLBUTYRATE & ANABOLIC OPTIMIZATION

A schematic representation of the trilateral molecular mechanisms by which pharmacological HMB supplementation exerts its protective and restorative effects in the highly catabolic surgical oncology patient. Note the blunt-ended line (⊣) denoting the inhibition of proteolysis.

A critical novelty highlighted in the synthesized clinical data is the integration of advanced nutritional pharmacology, specifically beta-hydroxy beta-methylbutyrate, combined with high-protein oral nutritional supplementation. Beta-hydroxy beta-methylbutyrate is a highly bioactive metabolite of the essential branched-chain amino acid leucine. Endogenously, less than five percent of dietary leucine is converted to beta-hydroxy beta-methylbutyrate, making direct pharmacological supplementation a metabolic necessity to achieve true therapeutic concentrations in the highly stressed surgical patient.[15] The precise molecular mechanism of beta-hydroxy beta-methylbutyrate relies on a sophisticated dual-action pathway that directly antagonizes surgical catabolism. Firstly, it aggressively inhibits protein degradation by downregulating the ubiquitin-proteasome proteolytic pathway, which is normally hyperactivated by surgical cortisol and circulating inflammatory cytokines. Secondly, it acts as a potent structural anabolite by directly stimulating the mammalian target of rapamycin (mTOR) signaling cascade. Specifically, through the enhanced phosphorylation of p70S6k and 4E-BP1, beta-hydroxy beta-methylbutyrate directly drives messenger RNA translation, exponentially upregulating de novo muscle protein synthesis. Furthermore, this specific metabolite actively preserves sarcolemmal integrity by acting as an essential precursor for endogenous cholesterol synthesis within the myocyte membrane, a critical protective factor during the mechanical stress of resistance training utilized in preoperative exercise protocols, as detailed in Figure 3.



FIGURE 4. INTRAMUSCULAR ADIPOSE TISSUE (IMAT) REMODELING & METABOLIC FLEXIBILITY

A graphical schematic detailing how older, sarcopenic skeletal muscle undergoing multimodal prehabilitation metabolically adapts by prioritizing the localized storage of dense lipid substrates (IMAT) to successfully meet newly enhanced functional demands without experiencing a decline in physical performance.

The long-term physiological analysis of sarcopenic patients revealed fascinating, highly complex dynamics regarding intramuscular adipose tissue. The pooled data indicated an initial acute reduction in intramuscular adipose tissue during the immediate surgical phase, followed by a subsequent rebound and stabilization at six months postoperatively. Crucially, this occurred despite continuous, significant improvements in functional metrics like the chair rise test and the six-minute walk test. This specific physiological phenomenon can be completely explained by examining age-related metabolic shifts and the precise metabolic fate of branched-chain amino acids in the older adult. In aging skeletal muscle, mitochondrial oxidation of branched-chain amino acids is frequently impaired.[16] Consequently, keto-isocaproate, a direct biochemical precursor in the beta-hydroxy beta-methylbutyrate pathway, may inadvertently activate the branched-chain alpha-keto acid dehydrogenase complex. In the absolute presence of persistent anabolic resistance typical of advanced age, the accelerated catabolism of keto-isocaproate can lead to the production of branched-chain fatty acids and acetyl-CoA. This surplus acetyl-CoA is then immediately diverted toward de novo lipogenesis, promoting lipid accumulation within the muscle tissue fascial planes. Crucially, this specifically documented increase in the Intramuscular Adipose Tissue index does not correlate with a decline in physical performance. Instead, it suggests a profound physiological remodeling process where older, sarcopenic muscle purposefully prioritizes the localized storage of dense lipid energy substrates to actively fuel the newly enhanced functional demands cultivated by the prehabilitation exercise regimens. The fact that mid-arm muscle area expanded concurrently with an increased Intramuscular Adipose Tissue index undeniably indicates that the total cross-sectional geometry of the muscle is increasing, simultaneously incorporating both newly hypertrophied myofibrils and strategically deposited energy reserves, detailed in Figure 4.

The remarkable reduction in Grade II pulmonary infections observed in the synthesized cohorts is rooted directly in the fundamental pathophysiology of respiratory mechanics.[17] Prehabilitation protocols universally incorporate rigorous aerobic conditioning, frequently utilizing high-intensity interval training guided by precise cardiopulmonary exercise testing, alongside targeted inspiratory muscle training. Major open or prolonged laparoscopic gastrointestinal surgery severely impairs diaphragmatic excursion and effectively suppresses the cough reflex due to intense abdominal incisional pain, inevitably leading to dependent atelectasis and subsequent pneumonia. Inspiratory muscle training utilizes specific threshold-loading devices to induce rapid, targeted hypertrophy of the diaphragm and the external intercostal muscles. Concurrently, high-intensity interval training aggressively challenges the cardiovascular system, forcing a rightward physiological shift in the anaerobic threshold and a massive upregulation of mitochondrial biogenesis in skeletal muscle. This definitively means the patient can sustain higher metabolic workloads postoperatively without resorting to inefficient anaerobic glycolysis and subsequent lactic acidosis. The resulting enhanced Forced Vital Capacity and Peak Expiratory Flow directly translate to a vastly superior mechanical ability to clear pulmonary secretions in the critical first seventy-two hours post-extubation, entirely explaining the drastic, observed drop in pulmonary complication rates.[18]

Finally, the systematic integration of psychological coping strategies within the multimodal framework aggressively addresses the neuroendocrine component of surgical stress. Preoperative anxiety and clinical depression are not merely subjective emotional states; they are potent, strictly measurable drivers of physiological detriment. High anxiety sustains elevated sympathetic nervous system tone and chronically high serum cortisol levels, which directly suppress cellular immunity, specifically blunting natural killer cell activity and cytotoxic T-cell proliferation. This prolonged immunosuppression directly increases the patient's biological susceptibility to postoperative infections. By systematically reducing anxiety through structured psychological counseling and active cognitive restructuring, multimodal prehabilitation effectively downregulates this deleterious neuroendocrine axis. The substantial improvements in the Quality of Recovery scores and the significant reductions in the Hospital Anxiety and Depression Scale documented in the pooled results absolutely prove that mentally preparing the patient is as physiologically crucial as physical conditioning. An empowered, actively engaged patient exhibits significantly superior compliance with postoperative mobilization and respiratory physiotherapy, creating a positive physiological feedback loop that undeniably accelerates total systemic recovery.[19]

While this synthesis provides robust physiological insights, minor clinical heterogeneity exists across the evaluated trials concerning the exact duration and intensity of the applied regimens, which is reflected in the moderate statistical heterogeneity quantified by the I^2 values. Furthermore, given the exact nature of structured physical exercise interventions, the absolute blinding of participating patients and administering personnel is an inherent logistical impossibility, introducing a minor potential risk of performance bias, although the strict reliance on universally graded objective complication criteria effectively minimizes this impact.[20]

4. Conclusion

Multimodal prehabilitation represents a paradigm-shifting evolution in the definitive management of major gastrointestinal oncology surgery. This rigorous quantitative synthesis proves that the strategic, proactive optimization of a patient's physical, nutritional, and psychological state fundamentally alters their physiological capacity to withstand surgical trauma. By combining targeted cardiopulmonary conditioning with advanced nutritional pharmacology to actively arrest the ubiquitin-proteasome pathway, multidisciplinary surgical teams can significantly attenuate the devastating catabolic decline traditionally associated with major abdominal resections. The resulting substantial reduction of severe pulmonary complications and the sustained preservation of functional independence firmly establish multimodal prehabilitation not as an optional adjunct, but as a critical physiological imperative in the modern landscape of surgical oncology.

5. References

1. Carli F, Bousquet-Dion G, Awasthi R. Effect of multimodal prehabilitation vs postoperative rehabilitation on 30-day postoperative complications for frail patients undergoing resection of colorectal cancer: a randomized clinical trial. JAMA Surg. 2020; 155(3): 233-42.
2. Bruns ERJ, van den Heuvel B, Buskens CJ. The effects of physical prehabilitation in elderly patients undergoing major surgery: a systematic review. Int J Surg. 2016; 36(Pt A): 33-41.
3. Minnella EM, Awasthi R, Loiselle SE. Effect of exercise and nutrition prehabilitation on functional capacity in esophagogastric cancer surgery: a randomized clinical trial. JAMA Surg. 2018; 153(12): 1081-9.
4. Gillis C, Li C, Lee L. Prehabilitation versus rehabilitation: a randomized control trial in patients undergoing colorectal resection for cancer. Anesthesiology. 2014; 121(5): 937-47.
5. Lambert JE, Hayes LD, Keegan TJ, Subar DA, Thomas CP. The impact of prehabilitation on patient outcomes in hepatobiliary, colorectal, and upper gastrointestinal cancer surgery: a PRISMA-accordant meta-analysis. Ann Surg. 2021; 274(1): 70-7.
6. Waterland JL, McCourt O, Edbrooke L. Efficacy of prehabilitation including exercise on postoperative outcomes following abdominal cancer surgery: a systematic review and meta-analysis. Front Surg. 2021; 8: 628848.
7. Barberan-Garcia A, Ubre M, Roca J. Personalised prehabilitation in high-risk patients undergoing elective major abdominal surgery: a randomized blinded controlled trial. Ann Surg. 2018; 267(1): 50-6.
8. Rombey T, Oellerich N, Lichter. Prehabilitation before major abdominal surgery: umbrella review of systematic reviews. BJS Open. 2021; 5(6): zrab122.
9. Mu GC, Tu YH, Xie HL. Multimodal prehabilitation enhances perioperative outcomes in gastric cancer patients: a single-center randomized controlled trial. Front Nutr. 2026; 12: 1676180.
10. Pesce A, Fabbri N, Colombari S. A randomized controlled clinical trial on multimodal prehabilitation in colorectal cancer patients to improve functional capacity: preliminary results. Surg Endosc. 2024; 38(12): 7440-50.
11. Bojesen RD, Dalton SO, Skou ST. Preoperative multimodal prehabilitation before elective colorectal cancer surgery in patients with WHO performance status I or II: randomized clinical trial. BJS Open. 2023; 7(6): zrad134.

12. Shua IYL, Tan YY, Yik V. Long-term outcomes of multimodal prehabilitation with high protein oral and HMB supplementation in sarcopenic surgical patients: The HEROS study. Nutrients. 2026; 18: 703.
13. Kleve G, Santa CD, Kristiansen F. Digital home-based multimodal prehabilitation of colorectal cancer patients prior to surgery (the dHOPE study): a non-inferiority clinical trial protocol. Front Digit Health. 2025; 7: 1609678.
14. van Rooijen S, Carli F, Dalton S. Multimodal prehabilitation in colorectal cancer patients to improve functional capacity and reduce postoperative complications: the first international randomized controlled trial for multimodal prehabilitation. BMC Cancer. 2019; 19(1): 98.
15. Molenaar CJL, Minnella EM, Coca-Martinez M, et al. Effect of Multimodal prehabilitation on reducing postoperative complications and enhancing functional capacity following colorectal cancer surgery: The PREHAB randomized clinical trial. JAMA Surg. 2023; 158(6): 572-81.
16. McIsaac DI, Hladkowicz E, Bryson GL. Home-based prehabilitation with exercise to improve postoperative recovery for older adults with frailty having cancer surgery: the PREHAB randomised clinical trial. Br J Anaesth. 2022; 129(1): 41-8.
17. Onerup A, Andersson J, Angenete E. Effect of short-term prehabilitation on postoperative complications and functional capacity after colorectal surgery: a randomized clinical trial. Ann Surg. 2022; 275(3): e544-e551.
18. Daniels SL, Lee MJ, George J. Prehabilitation in elective abdominal cancer surgery in older patients: systematic review and meta-analysis. BJS Open. 2020; 4(6): 1022-41.
19. West MA, Astin R, Moyses HE. Exercise prehabilitation may protect against the detrimental effects of neoadjuvant chemoradiotherapy on physical fitness in patients with locally advanced rectal cancer. Br J Surg. 2015; 102(13): 1598-605.
20. Hughes MJ, Hackney RJ, Lamb PJ, Wigmore SJ, Christopher Deans DA, Skipworth RJE. Prehabilitation before major abdominal surgery: a systematic review and meta-analysis. World J Surg. 2019; 43(7): 1661-68.